Selective and enantiospecific acylation of kappa opioid receptors by (1S,2S)-trans-2-isothiocyanato-N-methyl-N-[2-(1-pyrrolidinyl) cyclohexy l] benzeneacetamide. Demonstration of kappa receptor heterogeneity.
de Costa
B R
BR
Section on Drug Design and Synthesis, National Institute of Digestive, Diabetes and Kidney Diseases, Bethesda, Maryland 20892.
Rothman
R B
RB
Bykov
V
V
Jacobson
A E
AE
Rice
K C
KC
D000215:Acylation; D000818:Animals; D044482:Benzeneacetamides; D001575:Benzomorphans / Q000378:metabolism; D003510:Cyclohexanes / Q000494:pharmacology*; D006168:Guinea Pigs; D066298:In Vitro Techniques; D011759:Pyrrolidines / Q000378:metabolism / Q000494:pharmacology*; D011957:Receptors, Opioid / Q000378:metabolism*; D017473:Receptors, Opioid, kappa; D013237:Stereoisomerism
D044482:Benzeneacetamides; D001575:Benzomorphans; D003510:Cyclohexanes; D011759:Pyrrolidines; D011957:Receptors, Opioid; D017473:Receptors, Opioid, kappa; C058445:2-isothiocyanato-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)benzeneacetamide; C027248:bremazocine; C045444:U 69593